biotech
biotech Articles
The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference...
Published:
Last Updated:
The April 30 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Last Updated:
It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and even longer before profits can be considered.
Published:
Last Updated:
With evolving societal and regulatory landscapes, the upside potential of cannabis as a new investment strategy has emerged. Investors can use a number of ETFs to invest in the future of cannabis.
Published:
Last Updated:
With healthy living trends gaining ever more traction within the United States, they provide ample investment opportunity. ETFs help mitigate the risk of investing in individual fitness companies or...
Published:
Last Updated:
Osmotica Pharma shares jumped on Tuesday after the firm announced results from its late-stage trial for the treatment of ptosis (droopy eyelid).
Published:
Last Updated:
Cytokinetics shares took a step back on Monday after the firm announced that its midstage trial for ALS failed to meet expectations.
Published:
Last Updated:
It’s no simple task for a biotech giant to try to sell itself to investors as a value stock. That has been the case for some time when it comes to Gilead Sciences, Inc. (NASDAQ: GILD). After a long...
Published:
Last Updated:
Nabriva Therapeutics shares dropped sharply on Wednesday after the firm received a warning from the FDA for the New Drug Application seeking marketing approval of Contepo (fosfomycin).
Published:
Last Updated:
Hermispherx Biopharma shares shot up on Tuesday after the firm announced significant progress in its Ampligen recurrent ovarian cancer program at the University of Pittsburgh Medical Center.
Published:
Last Updated:
There may be some good news developing for those who suffer from Pompe Disease. Amicus Therapeutics, Inc. (NASDAQ: FOLD) has reported pre-clinical data from its Pompe disease gene therapy program and...
Published:
Last Updated:
The April 15 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Last Updated:
Even though tech stocks on average are posting far better gains that health care stocks, a fair number of health care stocks — biotechs specifically — are blowing these tech stocks out of the...
Published:
Last Updated:
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how much they are lagging...
Published:
Last Updated:
Jefferies did a deep dive into the health care sector, looking for underperforming stocks that could hold some solid value going forward.
Published:
Last Updated: